Impressive initial results from the MITCI Phase Ib trial suggest that Viralytics could push to the forefront of the crowded field of immune checkpoint inhibitor (ICI) combination therapies. The first six melanoma patients treated with Cavatak in combination with Yervoy (ipilimumab) experienced a higher response rate (67%) and lower serious adverse event rate (9%) than other prominent ICI combination therapies. These encouraging initial data bode well for the ongoing Phase Ib trials of Cavatak
05 May 2016
Eye-catching MITCI data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Eye-catching MITCI data
Viralytics (VLA:ASX) | 0 0 -4.6% | Mkt Cap: 175.3m
- Published:
05 May 2016 -
Author:
Dr Dennis Hulme -
Pages:
8
Impressive initial results from the MITCI Phase Ib trial suggest that Viralytics could push to the forefront of the crowded field of immune checkpoint inhibitor (ICI) combination therapies. The first six melanoma patients treated with Cavatak in combination with Yervoy (ipilimumab) experienced a higher response rate (67%) and lower serious adverse event rate (9%) than other prominent ICI combination therapies. These encouraging initial data bode well for the ongoing Phase Ib trials of Cavatak